Spyre Therapeutics, Inc. Common Stock

Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, generating approximately $403 million in gross proceeds. The offering is expected to close on April 16, 2026. Joint book-running managers include Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC.

Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease treatments, announced a proposed underwritten public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering is subject to market conditions and regulatory approval, with Jefferies LLC, Goldman Sa...

Spyre Therapeutics, a clinical-stage biotechnology company focused on IBD and immune-mediated diseases, announced a $300 million underwritten public offering of common stock with a potential additional $45 million option for underwriters. The offering is led by Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities as joi...

Spyre Therapeutics announced positive Phase 2 SKYLINE trial results for SPY001, an extended half-life anti-α4β7 antibody for moderate-to-severe ulcerative colitis. SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index score (p<0.0001) at Week 12, with secondary endpoints showing 40...

VR Adviser, LLC increased its position in Spyre Therapeutics by 1 million shares (estimated $25.78 million) in Q4, bringing total holdings to 3.68 million shares valued at $120.74 million (5.96% of AUM). Spyre Therapeutics, a preclinical-stage biotech company developing antibody therapies for inflammatory bowel disease, has seen its stock surge 1...